Awakn Life Sciences Corp. (AWKN: NEO) Clinic Roll-Out Addresses The Multi-Billion Dollar Addiction Treatment Industry With Psychedelics

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.

Awakn has a dual strategic focus:

1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.

Notable Highlights include:

• Strategic focus on better treating Addiction with psychedelics.
• World leading team focused on psychedelic drug and therapy research.
• Strong drug and therapy development pipeline, specifically targeting Addiction.
• Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery
• Filed provisional patent applications in the U.S. for two next-generation novel MDMA-derived new chemical entities
• Initiated a new chemical entity (NCE) drug discovery program
• Initiated a Ketamine research program
• Closed acquisition of leading Ketamine-Assisted Psychotherapy Clinic in Norway

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.